These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37014667)

  • 41. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
    Lachowiez CA; Loghavi S; Zeng Z; Tanaka T; Kim YJ; Uryu H; Turkalj S; Jakobsen NA; Luskin MR; Duose DY; Tidwell RSS; Short NJ; Borthakur G; Kadia TM; Masarova L; Tippett GD; Bose P; Jabbour EJ; Ravandi F; Daver NG; Garcia-Manero G; Kantarjian H; Garcia JS; Vyas P; Takahashi K; Konopleva M; DiNardo CD
    Blood Cancer Discov; 2023 Jul; 4(4):276-293. PubMed ID: 37102976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
    Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
    Montesinos P; de Botton S; Döhner H
    N Engl J Med; 2022 Jun; 386(26):2536-2537. PubMed ID: 35767450
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
    J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
    Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
    Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
    Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IDH Inhibitors in AML-Promise and Pitfalls.
    McMurry H; Fletcher L; Traer E
    Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
    Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
    Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
    J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Vydra J; Válková V; Čemusová B; Kolář M; Nováková L; Soukup P; Šálek C; Vraná M; Pytlík R; Lesný P; Vítek A; Cetkovský P; Marková M
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):365-371. PubMed ID: 30905537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ivosidenib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2023 Nov; 18(6):973-980. PubMed ID: 37855990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
    Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Megías-Vericat JE; Ballesta-López O; Barragán E; Montesinos P
    Blood Lymphat Cancer; 2019; 9():19-32. PubMed ID: 31413655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ivosidenib Deemed Safe, Effective in AML.
    Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
    Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ivosidenib: First Global Approval.
    Dhillon S
    Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.